290 related articles for article (PubMed ID: 7051959)
41. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Van Dyk JJ; Falkson G
Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
[TBL] [Abstract][Full Text] [Related]
42. [Case of malignant pheochromocytoma with successful control of systemic metastasis with CVD chemotherapy].
Minami T; Doi Y; Tetsuo H; Baba K; Seto S; Suzuki S; Hayano M; Yano S; Minami K; Oshibuchi E
Nihon Naika Gakkai Zasshi; 1996 Dec; 85(12):2078-80. PubMed ID: 9036176
[No Abstract] [Full Text] [Related]
43. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
44. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
45. [DTIC in malignant melanoma: a perspective (author's transl)].
Kokoschka EM
Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
[TBL] [Abstract][Full Text] [Related]
46. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
47. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Gershanovich ML; Akimov MA
Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth A; Wanek LA; Morton DL
J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
[TBL] [Abstract][Full Text] [Related]
49. Metastatic distribution in malignant melanoma. A 30-year autopsy study.
Akslen LA; Hove LM; Hartveit F
Invasion Metastasis; 1987; 7(5):253-63. PubMed ID: 3679740
[TBL] [Abstract][Full Text] [Related]
50. [Chemotherapy of malignant melanoma using DTIC].
Zaumseil RP; Fiedler H; Lübbe D
Dermatol Monatsschr; 1977 Nov; 163(11):905-14. PubMed ID: 590586
[No Abstract] [Full Text] [Related]
51. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
Pectasides D; Yianniotis H; Alevizakos N; Bafaloukos D; Barbounis V; Varthalitis J; Dimitriadis M; Athanassiou A
Br J Cancer; 1989 Oct; 60(4):627-9. PubMed ID: 2803936
[TBL] [Abstract][Full Text] [Related]
52. [Marked regression of melanoma metastases under combined chemotherapy].
Klemm-Mayer H; Rasokat H; Wagner G
Z Hautkr; 1984 Apr; 59(7):443-5. PubMed ID: 6730608
[TBL] [Abstract][Full Text] [Related]
53. A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma.
Presant CA; Bartolucci AA; Balch C; Troner M
Cancer; 1982 Apr; 49(7):1355-7. PubMed ID: 7037162
[TBL] [Abstract][Full Text] [Related]
54. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Quan W; Knupp C; Quan F; Walker P
Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
[TBL] [Abstract][Full Text] [Related]
55. [Regional intra-arterial chemotherapy with Dacarbazine in isolated liver metastases of a malignant melanoma].
Böckers M; Keller E; Bork K
Dtsch Med Wochenschr; 1988 Jan; 113(1):20-1. PubMed ID: 3335193
[TBL] [Abstract][Full Text] [Related]
56. [Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
Leyh F; Winzer M; Weber M; Hypa F
Z Hautkr; 1985 Jun; 60(12):961-72. PubMed ID: 4024678
[TBL] [Abstract][Full Text] [Related]
57. Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
Einhorn LH; Burgess MA; Vallejos C; Bodey GP; Gutterman J; Mavligit G; Hersh EM; Luce JK; Frei E; Freireich EJ; Gottlieb JA
Cancer Res; 1974 Aug; 34(8):1995-2004. PubMed ID: 4842252
[No Abstract] [Full Text] [Related]
58. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
59. Combined DTIC and cis-dichlorodiammineplatinum(II) therapy for patients with disseminated melanoma: a Northern California Oncology Group study.
Friedman MA; Kaufman DA; Williams JE; Resser KJ; Rosenbaum EH; Cohen RJ; Glassberg AB; Blume MR; Gershow J; Chan EY
Cancer Treat Rep; 1979 Mar; 63(3):493-5. PubMed ID: 371802
[No Abstract] [Full Text] [Related]
60. [Control of multiple skin and lung metastasis of malignant melanoma by combined DAV and OK-432 chemoimmunotherapy in association with large-scale administration of indomethacin].
Maeda K; Miura S; Kawamura M; Jimbow K
Gan To Kagaku Ryoho; 1984 Nov; 11(11):2434-7. PubMed ID: 6497401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
